Modern aspects of prophylaxis and therapy for venous thrombo-embolic disease.
Bergqvist
D
D
Department of Surgery, University Hospital, Uppsala, Sweden. David.Bergqvist@kirurgi.uu.se
D002809:Chondroitin Sulfates / Q000627:therapeutic use; D003871:Dermatan Sulfate / Q000627:therapeutic use; D003911:Dextrans / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004338:Drug Combinations; D005343:Fibrinolytic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D006495:Heparin, Low-Molecular-Weight / Q000008:administration & dosage / Q000627:therapeutic use*; D006497:Heparan Sulfate / Q000627:therapeutic use; D006801:Humans; D011655:Pulmonary Embolism / Q000517:prevention & control; D013923:Thromboembolism / Q000188:drug therapy / Q000517:prevention & control*; D013924:Thrombophlebitis / Q000188:drug therapy / Q000517:prevention & control*
D002809:Chondroitin Sulfates; D003871:Dermatan Sulfate; D003911:Dextrans; D004338:Drug Combinations; D005343:Fibrinolytic Agents; D006495:Heparin, Low-Molecular-Weight; D006497:Heparan Sulfate; C035838:danaparoid